Rapt stock news drivers#
Rapt stock news upgrade#

It focuses on discovering, developing and commercializing. was incorporated in 2015 and is headquartered in South San Francisco, California. operates as a clinical stage immunology-based biopharmaceutical company. and changed its name to RAPT Therapeutics, Inc. RAPT Therapeutics (NASDAQ:RAPT) Intraday Stock Chart Monday 6 December 2021 Your Recent History LSE.

Want the latest recommendations from Zacks Investment Research Today, you can download 7 Best Stocks for the Next 30 Days. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Rapt stock news upgrade#

The company was formerly known as FLX Bio, Inc. 29.945-0.115 (-0.38) Upgrade to Real-Time Regular Market. RAPT THERAPTICS doesnt appear a compelling earnings-beat candidate. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - RAPT Therapeutics, Inc.

Rapt stock news drivers#

Our cutting-edge science is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of cancer and inflammation, and improve and empower countless lives. RAPT Therapeutics Announces Proposed Public Offering of Common Stock June 14, 2021.

Risk Disclaimer: Trading in financial instruments and including but not limited. RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by a bold missionto conquer cancer and inflammatory disease in our lifetime. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. Stock Market News, Quotes, Charts and Financial Information. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.